Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 11.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of EPRX.TO is 14 and suggests 23% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Data is available to registered users only
Buy
Sell